Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies
Fifty1 AI Labs (OTC:FITY) has completed the world's largest and most comprehensive Sickle Cell Disease (SCD) study, backed by The Gates Foundation. The groundbreaking research analyzed a decade of real-world patient data, creating an unprecedented mapping of disease progression and treatment outcomes.
The study, conducted in collaboration with the University of Pittsburgh School of Medicine and Stellenbosch University Centre, aims to accelerate the development of gene-based therapies and repurposed medicines. The research findings will be presented at a specialist conference in Senegal and have been submitted to a leading hematology journal.
With 7.74 million people worldwide affected by SCD, primarily in sub-Saharan Africa, this AI-driven analysis represents a significant step toward developing affordable treatments for this underserved genetic disorder.
Fifty1 AI Labs (OTC:FITY) ha completato il pi霉 ampio e dettagliato studio al mondo sulla Sickle Cell Disease (SCD), sostenuto da The Gates Foundation. La ricerca, all'avanguardia, ha analizzato un decennio di dati real-world dei pazienti, realizzando una mappatura senza precedenti dell'evoluzione della malattia e degli esiti terapeutici.
Lo studio, condotto in collaborazione con la University of Pittsburgh School of Medicine e il Stellenbosch University Centre, mira ad accelerare lo sviluppo di terapie geniche e il riposizionamento di farmaci esistenti. I risultati saranno presentati a una conferenza specialistica in Senegal e sono stati sottoposti a una rivista leader in ematologia.
Con circa 7,74 milioni di persone colpite nel mondo, soprattutto nell'Africa subsahariana, questa analisi basata sull'IA rappresenta un passo importante verso lo sviluppo di trattamenti accessibili per questa patologia genetica spesso trascurata.
Fifty1 AI Labs (OTC:FITY) ha completado el mayor y m谩s exhaustivo estudio mundial sobre la Sickle Cell Disease (SCD), con el apoyo de The Gates Foundation. Esta investigaci贸n pionera analiz贸 una d茅cada de datos reales de pacientes y ha trazado, sin precedentes, la progresi贸n de la enfermedad y los resultados de los tratamientos.
El estudio, realizado en colaboraci贸n con la University of Pittsburgh School of Medicine y el Stellenbosch University Centre, pretende acelerar el desarrollo de terapias g茅nicas y la reutilizaci贸n de medicamentos ya existentes. Los hallazgos se presentar谩n en una conferencia especializada en Senegal y se han enviado a una revista l铆der en hematolog铆a.
Con aproximadamente 7,74 millones de personas afectadas en el mundo, principalmente en el 脕frica subsahariana, este an谩lisis impulsado por IA supone un avance relevante hacia tratamientos asequibles para este trastorno gen茅tico desatendido.
Fifty1 AI Labs (OTC:FITY)臧赌 The Gates Foundation鞚� 歆�鞗愳潉 氚涭晞 靹戈硠鞐愳劀 臧赌鞛� 韥碃 韽磩鞝侅澑 瓴胳儊鞝來槇甑硲(SCD) 鞐瓣惮毳� 鞕勲頄堨姷雼堧嫟. 鞚� 須嶊赴鞝侅澑 鞐瓣惮電� 10雲勱皠鞚� 鞁れ牅 頇橃瀽 雿办澊韯半ゼ 攵勳劃頃� 歆堧硲 歆勴枆瓿� 旃橂 瓴瓣臣毳� 鞝勲 鞐嗢澊 靸侅劯頌� 霃勳嫕頇旐枅鞀惦媹雼�.
頃措嫻 鞐瓣惮電� University of Pittsburgh School of Medicine 氚� Stellenbosch University Centre鞕� 順戨牓頃� 歆勴枆霅橃棃鞙茧┌, 鞙犾爠鞛� 旮半皹 旃橂氩曣臣 旮办〈 鞎诫鞚� 鞛鞝來檾毳� 臧赌靻嶍檾頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞐瓣惮 瓴瓣臣電� 靹鸽劋臧堨潣 鞝勲 頃欗殞鞐愳劀 氚滍憸霅� 鞓堨爼鞚措┌ 欤检殧 順堨暋頃� 鞝�雱愳棎 鞝滌稖霅橃棃鞀惦媹雼�.
鞝� 靹戈硠 鞎� 774毵� 氇�鞚� 鞚� 歆堩櫂鞙茧 瓿犿喌氚涥碃 鞛堨溂氅� 欤茧 靷晿霛� 鞚措偍 鞎勴攧毽勾鞐� 歆戩霅橃柎 鞛堨姷雼堧嫟. 鞚措矆 AI 旮半皹 攵勳劃鞚� 鞚� 靻岇櫢霅� 鞙犾爠 歆堩櫂鞐� 雽�頃� 鞝戧芳 臧赌電ロ暅 旃橂氩� 臧滊皽搿� 雮橃晞臧赌電� 欷戩殧頃� 歆勳爠鞛呺媹雼�.
Fifty1 AI Labs (OTC:FITY) a men茅 la plus vaste et la plus compl猫te 茅tude mondiale sur la Sickle Cell Disease (SCD), soutenue par The Gates Foundation. Cette recherche innovante a analys茅 une d茅cennie de donn茅es patients r茅elles, 茅tablissant une cartographie in茅dite de la progression de la maladie et des r茅sultats des traitements.
L'茅tude, r茅alis茅e en collaboration avec la University of Pittsburgh School of Medicine et le Stellenbosch University Centre, vise 脿 acc茅l茅rer le d茅veloppement de th茅rapies g茅niques et le repositionnement de m茅dicaments existants. Les conclusions seront pr茅sent茅es lors d'une conf茅rence sp茅cialis茅e au S茅n茅gal et ont 茅t茅 soumises 脿 une revue majeure d'h茅matologie.
Avec environ 7,74 millions de personnes touch茅es dans le monde, principalement en Afrique subsaharienne, cette analyse pilot茅e par l'IA repr茅sente une avanc茅e significative vers des traitements abordables pour ce trouble g茅n茅tique peu pris en charge.
Fifty1 AI Labs (OTC:FITY) hat die weltweit gr枚脽te und umfassendste Studie zur Sickle Cell Disease (SCD) abgeschlossen, unterst眉tzt von The Gates Foundation. Die bahnbrechende Untersuchung wertete ein Jahrzehnt realer Patientendaten aus und erstellte eine beispiellose Kartierung des Krankheitsverlaufs und der Behandlungsergebnisse.
Die Studie, durchgef眉hrt in Zusammenarbeit mit der University of Pittsburgh School of Medicine und dem Stellenbosch University Centre, zielt darauf ab, die Entwicklung gentherapeutischer Ans盲tze und das Repurposing vorhandener Medikamente zu beschleunigen. Die Ergebnisse werden auf einer Fachkonferenz in Senegal vorgestellt und einer f眉hrenden h盲matologischen Fachzeitschrift zur Ver枚ffentlichung eingereicht.
Mit rund 7,74 Millionen Menschen weltweit, vor allem in Subsahara-Afrika, stellt diese KI-gest眉tzte Analyse einen wichtigen Schritt zur Entwicklung erschwinglicher Behandlungen f眉r diese bislang unterversorgte genetische Erkrankung dar.
- Collaboration with prestigious partners including The Gates Foundation and major research institutions
- AI technology successfully analyzed a decade of real-world patient data
- Research could accelerate development of new treatments through gene therapy and drug repurposing
- Addresses large market opportunity with 7.74 million affected patients globally
- No immediate revenue generation from the research
- Timeline for developing actual treatments remains uncertain
- Significant competition in gene therapy and drug development space
Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved diseases
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN --听Fifty1 AI Labs, Inc. (), a leader in AI-powered drug repurposing and precision medicine, today announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth of real-world patient data, the study mapped disease progression and treatment outcomes at an unprecedented scale鈥攎arking a major milestone in the fight against this life-threatening genetic disorder.
Funded by听The Gates Foundation听and conducted in collaboration with听scientists from the University of Pittsburgh School of Medicine听and the听Stellenbosch University Centre for Infectious Diseases in South Africa, the groundbreaking research delivers the most detailed understanding to date of SCD's clinical landscape.
"This is more than a scientific achievement鈥攊t's a turning point," said听Paul Arora, CEO of Fifty1 AI Labs. "By combining AI-driven analytics with world-class partnerships, we are accelerating the path toward affordable, effective treatments for millions who have long been overlooked."
The study's findings have been submitted to one of the world's most respected hematology journals and will be presented this September at a specialist conference in Senegal, drawing leading global experts in blood disorders.
Beyond its academic and clinical impact, the study serves as a catalyst for听next-generation gene-based therapies听and the听repurposing of existing medicines鈥攖wo approaches that can dramatically shorten timelines and reduce costs in bringing new treatments to market. With an estimated听7.74 million people worldwide听living with SCD鈥攎ost in sub-Saharan Africa and among people of African descent鈥攖his work addresses one of the highest-burden, least-served health challenges globally.
Powered by听advanced analytics technologies pioneered at Fifty1 AI Labs, the project demonstrates how AI can mine real-world clinical data at scale, uncovering insights that can transform treatment strategies across multiple disease areas.
About Fifty1 AI Labs, Inc.
Fifty1 AI Labs is revolutionizing drug development through AI-driven analytics, focusing on uncovering novel therapeutic applications for existing drugs and developing precision medicine solutions. The company's platform integrates large-scale clinical, genomic, and patient outcome data to accelerate treatment innovation across global health challenges.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
听| (877) 505-5006
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of gene-based therapies and repurposed treatments for Sickle Cell Disease, the anticipated presentation of study findings at a specialist conference, and the ability of Fifty1 AI Labs' platform to transform treatment strategies across multiple disease areas, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of clinical trials, regulatory approvals, the efficacy and safety of potential treatments, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 AI Labs' filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
What is the significance of Fifty1 AI Labs' (OTC:FITY) Sickle Cell Disease study?
Who are the key partners in Fifty1 AI Labs' SCD research?
How many people could benefit from Fifty1 AI Labs' SCD research?
When will Fifty1 AI Labs (FITY) present their SCD study findings?
How does Fifty1 AI Labs' technology contribute to SCD research?
